

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated May 29, 2024 and September 3, 2024 in relation to, among others, the issuance of filing notice by CSRC and the listing approval granted by the Stock Exchange regarding the implementation of the H share full circulation programme of the Company (the “**Announcements**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

### **COMPLETION OF THE H SHARE FULL CIRCULATION**

The Board is pleased to announce that the conversion of an aggregate of 120,463,260 Unlisted Shares into H Shares was completed on September 4, 2024 and the listing of such Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on September 5, 2024.

## SHAREHOLDING STRUCTURE

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Description of Shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	Number of Shares	Approximate percentage	Number of Shares	Approximate percentage
Unlisted Shares	145,607,656	38.92%	25,144,396	6.72%
H Shares	<u>228,550,039</u>	<u>61.08%</u>	<u>349,013,299</u>	<u>93.28%</u>
Total	<u><u>374,157,695</u></u>	<u><u>100.00%</u></u>	<u><u>374,157,695</u></u>	<u><u>100.00%</u></u>

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Hong Kong, September 4, 2024

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*